Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.

CONCLUSIONS: The STEP program evaluates the efficacy and safety of semaglutide 2.4 mg subcutaneously once weekly in a broad population. The trials will provide insights on WM in people with obesity with and without type 2 diabetes and on long-term follow-up. PMID: 32441473 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/32441473?dopt=Abstract

Source: Obesity - May 24, 2020 Category: Eating Disorders & Weight Management Authors: Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B, Lingvay I, Thomsen M, Wadden TA, Wharton S, Wilding JPH, Rubino D Tags: Obesity (Silver Spring) Source Type: research